Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00925301
Recruitment Status : Completed
First Posted : June 22, 2009
Last Update Posted : May 2, 2016
Information provided by (Responsible Party):
Amicus Therapeutics

June 19, 2009
June 22, 2009
May 2, 2016
August 2009
July 2012   (Final data collection date for primary outcome measure)
kidney GL-3 (assessed histologically in kidney biopsy samples) [ Time Frame: 6 months ]
Same as current
Complete list of historical versions of study NCT00925301 on Archive Site
  • urine GL-3 levels [ Time Frame: 6 months ]
  • renal function (assessed by iohexol GFR, eGFR, and 24-hour urine protein) [ Time Frame: 6 months ]
  • safety and tolerability [ Time Frame: 12 months ]
Same as current
Not Provided
Not Provided
Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamics of AT1001 in Patients With Fabry Disease and AT1001-Responsive GLA Mutations
The purpose of this study is to compare the effect of AT1001 (migalastat hydrochloride) versus placebo on kidney GL-3.

This double-blind, randomized, placebo-controlled study will be conducted in 60 patients at approximately 40 sites worldwide. The study will consist of two stages and an open-label treatment extension phase:

Stage 1 includes a screening period of up to 2 months followed by a 6-month treatment period which will involve 4 visits to the clinic. Patients will be randomized in equal proportions to receive either AT1001 or placebo.

After completing the 6-month double-blind phase, all patients will enter Stage 2 of the study and receive AT1001 in an open-label manner. Stage 2 treatment will last for 6 months and will involve 4 visits to the clinic.

Subjects who complete both Stage 1 and Stage 2 of the study as scheduled may be offered the opportunity to participate in an open-label treatment extension phase with AT1001. The open-label treatment extension phase will last 12 months and will involve 2 visits to the clinic. A follow-up visit will be undertaken 1 month following completion or discontinuation from the open-label treatment extension. Subjects completing the 12 month open-label treatment extension and providing consent to enter a separate long term extension will not be required to complete this follow-up visit.

Study assessments will include clinical laboratory tests, 12-lead ECG, kidney biopsy, kidney function testing, echocardiography, and patient reported outcomes.

Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Fabry Disease
  • Drug: migalastat hydrochloride
    oral capsule every other day
    Other Names:
    • AT1001
    • Galafold
  • Drug: Placebo
    oral capsule every other day
  • Experimental: Galafold (AT1001) Oral Capsule
    Migalastat HCl 150 mg capsule is taken every other day for 6 months and optional 6 month treatment extension
    Intervention: Drug: migalastat hydrochloride
  • Placebo Comparator: Placebo Oral Capsule
    Placebo capsule is taken every other day for 6 months.
    Intervention: Drug: Placebo

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
January 2014
July 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or female between the ages of 16 and 74 diagnosed with Fabry disease
  2. Confirmed GLA mutation that has been shown to be responsive to AT1001 in vitro
  3. Subject has never been treated with ERT or has not received ERT for 6 consecutive months or longer before the screening visit for the study
  4. Urine GL-3 greater than or equal to four times the upper limit of normal at Screening
  5. Subjects taking angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) must be on a stable dose for a minimum of 4 weeks before the baseline visit
  6. Women who can become pregnant and all men agree to be sexually abstinent or use medically accepted methods of birth control during the study and for 30 days after study completion
  7. Subject is willing and able to provide written informed consent, and assent if applicable

Exclusion Criteria:

  1. Subject has undergone or is scheduled to undergo kidney transplantation, or is currently on dialysis
  2. eGFR < 30 mL/min/1.73m2 (CKD Stage 4 or 5) based on MDRD equation
  3. QTc ≥ 450 msec for males or ≥ 470 msec for females at Screening NOTE: Protocol Amendment 2.1 eliminates Exclusion Criterion #3.
  4. Pregnant or breast-feeding
  5. History of allergy or sensitivity to study medication (including excipients) or other iminosugars (e.g., miglustat, miglitol)
  6. Subject is treated or has been treated with any investigational drug within 30 days of study start
  7. Subject is currently treated or has ever been treated with AT1001
  8. Any intercurrent condition or concomitant medication use considered to be an absolute contraindication to kidney biopsy or that may preclude accurate interpretation of study data
  9. Otherwise unsuitable for the study, in the opinion of the Investigator
Sexes Eligible for Study: All
16 Years to 74 Years   (Child, Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Argentina,   Australia,   Belgium,   Brazil,   Canada,   Denmark,   Egypt,   France,   Germany,   Italy,   Netherlands,   Poland,   South Africa,   Spain,   Turkey,   United Kingdom,   United States
Chile,   Israel
Not Provided
Not Provided
Amicus Therapeutics
Amicus Therapeutics
Not Provided
Study Director: Medical Monitor, Clinical Research Amicus Therapeutics
Amicus Therapeutics
March 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP